Artiva Biotherapeutics maintains a Buy rating due to FDA agreement on a single phase 3 trial for its AlloNK plus rituximab treatment targeting refractory rheumatoid arthritis (RA). Early studies showed strong response rates, addressing a significant unmet need in 3rd-line RA patients in the U.S., a market with $5 billion in spending. The company raised $300 million to fund late-stage trials and expand its pipeline into other autoimmune disorders. Phase 3 trial is set to start in the second half of 2026, with data expected by the second half of 2028.
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
Worldline has announced a conference call to discuss its H1 2026 financial results on July 30, 2026, at 6:30 pm CET. The event will be accessible via webcast, and sell-side analysts can participate in a Q&A session by pre-registering. The press relea...
Ipsen Pharma conducted a share buy-back program from July 6 to July 10, 2026, repurchasing a total of 28,541 shares. The average purchase price during this period was €166.05 per share. This buy-back activity reflects Ipsen's strategy to manage its c...
